Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice

• Published in: Journal of dermatological science 2018-03, Vol.89 (3), p.248-257
• Main Authors: Choi, Hyeongwon, Kim, Dong-jin, Nam, Seungwoo, Lim, Sunki, Hwang, Jae-Sung, Park, Ki Sook, Hong, Hyun Sook, Won, Younsun, Shin, Min Kyung, Chung, Eunkyung, Son, Youngsook
• Format: Article
• Language: English
• Subjects: Animals; Atopic dermatitis; Body Water - metabolism; Cells, Cultured; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - metabolism; Dermatitis, Atopic - pathology; Epidermis - drug effects; Epidermis - innervation; Epidermis - pathology; Male; Mice; NC/Nga mice; Nerve Fibers - pathology; Nerve Growth Factor - analysis; Picryl Chloride; Pruritus - drug therapy; Pruritus - pathology; Semaphorin-3A - analysis; Skin - drug effects; Skin - metabolism; Skin barrier; Substance P; Substance P - pharmacology; Substance P - therapeutic use; TNCB
• ISSN: 0923-1811; 1873-569X
• DOI: 10.1016/j.jdermsci.2017.11.013

•Topical Substance P treatment reduced AD-like symptoms in TNCB-induced NC/Nga mice.•Topical Substance P treatment reduced epidermal acanthosis and expressed normal keratin profiles in AD-like mice.•Topical Substance P treatment regulated both small nerve attraction and repulsion factors in AD-like skin.•Topical Substance P treatment recovered skin barrier function and reduced pruritus in AD-like mice. Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus and eczematous lesion. Substance P (SP) is an 11-amino-acid endogenous neuropeptide that belongs to the tachykinin family and several reports recently have supported the anti-inflammatory and tissue repairing roles of SP. In this study, we investigated whether SP can improve AD symptoms, especially the impaired skin barrier function, in 2, 4, 6-trinitrochlorobenzene (TNCB)-induced chronic dermatitis of NC/Nga mice or not. AD-like dermatitis was induced in NC/Nga mice by repeated sensitization with TNCB for 5 weeks. The experimental group designations and topical treatments were as follows: vehicle group (AD-VE); SP group (AD-SP); and SP with NK1R antagonist CP99994 (AD-SP-A) group. Histological analysis was performed to evaluate epidermal differentiation, dermal integrity, and epidermal nerve innervation in AD-like lesions. The skin barrier functions and pruritus of NC/Nga mice were evaluated by measuring transepidermal water loss (TEWL) and scratching behavior, respectively. Topical SP treatment resulted in significant down-regulation of Ki67 and the abnormal-type keratins (K) K6, K16, and K17, restoration of filaggrin and claudin-1, marked reduction of TEWL, and restoration of basement membrane and dermal collagen deposition, even under continuous sensitization of low dose TNCB. In addition, SP significantly reduced innervation of itch-evoking nerve fibers, gelatinase activity and nerve growth factor (NGF) expression in the epidermis but upregulated semaphorin-3A (Sema3A) expression in the epidermis, along with reduced scratching behavior in TNCB-treated NC/Nga mice. All of these effects were completely reversed by co-treatment with the NK1R antagonist CP99994. In cultured human keratinocytes, SP treatment reduced expression of TGF-α, but upregulated TGF-β and Sema3A. Topically administered SP can restore normal skin barrier function, reduce epidermal infiltration of itch-evoking nerve fibers in the AD-like skin lesions, and alleviate scratching behavior. Thus,